Identification

Name
CAT-213
Accession Number
DB05429
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

CAT-213 is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in allergic rhinitis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

CAT-213 targets eotaxin, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. During an allergic response the levels of eotaxin1 are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders.

TargetActionsOrganism
UEotaxinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Main S, Handy R, Wilton J, Smith S, Williams L, Fou LD, Andrews J, Conroy LA, May R, Anderson I, Vaughan TJ: A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy. J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404. Epub 2006 Sep 14. [PubMed:16973884]
  2. Dent G, Hadjicharalambous C, Yoshikawa T, Handy RL, Powell J, Anderson IK, Louis R, Davies DE, Djukanovic R: Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care Med. 2004 May 15;169(10):1110-7. Epub 2004 Mar 4. [PubMed:15001461]
External Links
PubChem Substance
347910132

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Chemokine activity
Specific Function
In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils, a prominent feature of allergic inflammatory reactions. Binds to CCR3.
Gene Name
CCL11
Uniprot ID
P51671
Uniprot Name
Eotaxin
Molecular Weight
10731.7 Da

Drug created on November 18, 2007 11:24 / Updated on November 06, 2017 06:45